Register to receive a free U.S. Market Report Suite for Gynecological Devices report synopsis and brochure

Luminelle DTx Hysteroscopy System has received its 510(k) clearance from the FDA with a dual-indication for both hysteroscopy and cystoscopy.  The Luminelle DTx Hysteroscopy System is small, easy to use, cost effective and has the potential for an affordable, accurate patient diagnosis and/or therapeutic procedure in one doctor’s office visit. The system went from concept to commercialization in just 25 months time and was designed and produced using 95% United States based supply chain.

Today, about 76 percent of hysteroscopy procedures take place in the operating room.

“Since the best technology is typically only available in the operating room, many physicians and patients opt to skip the hysteroscopy and either perform a blind biopsy or go straight to surgery, without taking a good look inside of the uterus,” explains Dr. Amy Garcia, MD FACOG; Director – Center for Women’s Surgery; Institute for Hysteroscopy Training, Albuquerque, NM. “An in-office system that is easy to use, prevents a blind biopsy and allows the physician to offer either a therapeutic diagnosis or a biopsy under visualization elevates the standard for uterine care.”

The technology of the Luminelle DTx Hysteroscopy System allows physicians to see the uterus’ internal lining from an optimal distance with clarity thus enabling identification of suspicious tissue, perform a biopsy under visualization, and offer a potentially faster diagnosis, treatment and recovery time for the patient.

“Most operating room equipment is cost and space prohibitive for standard office use. We created an elegant and ergonomic system with visualization quality comparable to that of the OR, and that is comfortable for both physician and patient,” explains Allison London Brown, CEO of UVision360, the medical device company responsible for the rapid design and launch of the device. “Our system is a fully-integrated hysteroscopy/cystoscopy system with a value-based cost to provide better accessibility for the changing needs of today’s GYN. The combined features lead to the potential for better care for women, earlier detection, and improved health outcomes.”

Source: https://www.prnewswire.com/news-releases/fda-approves-new-femtech-device-to-enhance-quality-of-care-for-the-uterus-300700096.html

For Further Information

More on the gynecological device market in the U.S. can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Gynecological Devices. The suite covers reports on the following markets: assisted reproduction devices, endometrial ablation, endometrial resection, uterine fibroid embolization, hysteroscopes, colposcopes, transcervical female sterilization, female urinary incontinence slings, laser technology, fluid management equipment, pelvic organ prolapse repair devices and hysterosalpingography catheters.

The iData report series on gynecological devices covers the U.S., Asia-Pacific and 15 countries in Europe including Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about gynecological market data or procedure data, register online or email us at [email protected] for a U.S. Market Report Suite for Gynecological Devices brochure and synopsis.